Healthcare / Medical DevicesStockholm
$0.39
+0.01 (+3.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-12.1M · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-334.8%
↓Gross Margin
274.0%
↑Debt/Equity
0.68
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-26.3%
FCF CAGR
—
FCF margin
-784.8%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.4M · net income $-8.9M · FCF $-11.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.4M | $1.4M | $2.1M | $3.6M | $3.6M |
| Net Income | $-8.9M | $-8.9M | $-11.7M | $-14.2M | $-14.4M |
| EBITDA | $-7.8M | $-7.8M | $-10.4M | $-13.0M | $-13.4M |
| EPS | -0.11 | -0.11 | -0.36 | -1.24 | -1.34 |
| Gross Margin | 274.0% | 274.0% | 89.8% | 55.5% | 59.3% |
| Operating Margin | -595.5% | -595.5% | -522.3% | -391.9% | -402.9% |
| Net Margin | -623.8% | -623.8% | -545.0% | -396.9% | -403.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.68 | 0.68 | 1.21 | 0.25 | 0.05 |
| Current Ratio | 0.61 | 0.61 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.2M | $-11.2M | $-12.1M | $-15.5M | $-14.3M |
| Returns | |||||
| ROE | -334.8% | -334.8% | -855.5% | -301.9% | -77.6% |
| Valuation | |||||
| P/B | 12.03 | 12.03 | 7.35 | 1.27 | 2.95 |
| Growth & Yield | |||||
| Revenue Growth | -33.5% | -33.5% | -40.1% | 0.3% | — |
| EPS Growth | 70.0% | 70.0% | 70.9% | 7.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.36 → -0.11
Residual
+42.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.